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Early and accurate diagnosis of invasive candidiasis (IC) is very important. In this study,
a lateral flow immunoassay (LFIA) was developed to detect antibody against Candida
albicans enolase (Eno). Colloidal gold particle labeled mouse anti human IgG (1.0mg/L)
was used as the detector reagent. Recombinant enolase (rEno, 1.0mg/L) and goat anti
IgG (1.0mg/L) were immobilized in test and control lines, respectively, of a nitrocellulose
membrane, acting as the capture reagents. The LFIA was used to detect anti Eno in 38
sera from clinically proven IC patients, as well as in 50 healthy control subjects. Compared
with an indirect ELISA designed as a reference test, the specificity and sensitivity of
the LFIA were 98.2 and 84.8%, respectively. Excellent agreement between the results
obtained by ELISA and the LFIA (κ = 0.851) was observed in this study. In addition, the
agreement between the blood culture results and LFIA test is strong (κ = 0.658). The
data presented in the study indicate that the LFIA test is a suitable tool for the serological
surveillance of IC in the field or in poorly equipped laboratories.
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INTRODUCTION
Morbidity and mortality caused by invasive candidiasis (IC) including candidemia continues to
increase worldwide in both immuno-compromised and immuno-competent patients (Pappas,
2006; Kullberg and Arendrup, 2015). A long-term intensive care unit (ICU) stay, abdominal
surgery, acute necrotizing pancreatitis, hematologic malignant disease, and the use of broad-
spectrum antibiotics are considered the leading factors for developing IC.
Early and accurate diagnosis for IC is very important for providing timely antifungal therapy
in IC patients. Until recently, a blood culture has been considered the golden standard test for IC
diagnosis (Clancy and Nguyen, 2013). A weakness of blood culture is its low sensitivity, which is
estimated as low as approximately 50% considering Candida cells might be rapidly eliminated from
blood circulation (Schell et al., 2012). Another notable shortcoming for blood cultures is that it is
time consuming: the time to positivity can take as long as 8 days (Pfeiffer et al., 2011). Non-culture
diagnostics were considered beneficial supplements for cases that aremissed by blood culture. From
one perspective, polymerase chain reaction (PCR) fulfills most of the criteria for clinical rapid IC
diagnosis (Clancy andNguyen, 2013). However, methodological standardization remains a primary
concern for clinical study and use. Another approach for diagnosing IC is the detection of Candida
cell components including β-D-glucan (BDG) and mannan. These tests are currently available in
the commercial market and are usually used in combination with classical clinical, radiological,
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andmicrobiological findings for early diagnosis of invasive fungal
infections (IFIs). However, false positive results of mannan or
BDG-based detection tests have been described in many cases
(Adam et al., 2004; Ostrosky-Zeichner et al., 2005; Zandijk et al.,
2008).
Decade-long efforts have been made to establish a
serologic diagnostic assay by detecting host antibodies against
Candida components for rapidly diagnosing IC, but none
are widespread in clinical use. Enolase (Eno), also known as
phosphopyruvate hydratase, is a metalloenzyme responsible
for catalyzing the conversion of 2-phosphoglycerate (2-PG) to
phosphoenolpyruvate (PEP). For Candida albicans, this protein
is present in both the cytoplasm and inner layers of the cell wall
(Vialás et al., 2012). Previous works showed that this enzyme
can elicit an antibody response in the infected host (Montagnoli
et al., 2004; Pitarch et al., 2006). Among the molecular candidates
for IC serodiagnosis, enolase is one of the most commonly
studied, and it has a high diagnostic value. Several studies have
demonstrated promising results for the diagnostic utility of
detecting antibodies against Eno (Laín et al., 2007; Clancy et al.,
2008; Li et al., 2013).
In this study, using recombinant Eno (rEno) ofC. albicans (He
et al., 2015), we developed a lateral flow immunoassay (LFIA)
for the detecting human IgG antibodies against Eno. The test is




The human serum specimen study protocol was approved by
the Ethics Committee of Bethune International Peace Hospital
and complies with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involving
humans.
Study Population and Serum Specimens
All patients were admitted to Bethune International Peace
Hospital, Shijiazhuang, China, from October 2011 to May
2015. Following the criteria of the European Organization for
the Research and Treatment of Cancer/Mycoses Study Group
[EORTC/MSG] (Ascioglu et al., 2002), 38 proven IC patients and
50 healthy subjects were enrolled in this study. For the proven
IC patients, 38 strains of Candida pathogens were identified by
blood culture, including 17 strains of C. albicans, 7 strains of
C. tropicalis, 6 strains of C. parapsilosis, 4 strains of C. glabrata, 2
strains of C. lusitaniae, and 2 strains of C. krusei. To provide data
on the assay specificity, the healthy subjects group has a similar
age and sex distribution as the proven IC group.
For subjects with IC, the sample was collected within 72 h
after positive blood culture results were obtained. This assured
uniformity and that all subjects had active disease at the
time of enrollment. All sera samples were stored at −80◦C
before analysis. Data, including the age, primary condition, and
clinical stage, were obtained from the clinical records. Baseline
characteristics of all subjects enrolled in this study are shown in
Table 1.
TABLE 1 | Base-line characteristics of the 88 subjects included in the
study.
Characteristic Number (%) or
mean ± S.D.
Invasive Control
candidiasis (n = 38) subjects (n = 50)
Age, mean years ±SD 58.6 ± 20.2 60.1 ± 18.6
SEX
Male 25 (65.8) 32 (64.0)
Female 13 (34.2) 18 (36.0)
PRIMARY CONDITION
Hematological malignancy 3 (7.9) 0
Solid tumor 6 (15.8) 0
Severe burn injuries 13 (34.2) 0
Respiratory dysfunctiona 6 (15.8) 0
Gastrointestinal pathologyb 7 (18.4) 0
Othersc 3 (7.9) 0
RISK FACTORS FOR IC
Broad spectrum antibiotics 22 (57.9) 0
Immunosuppressive therapy 11 (28.9) 0
Central venous catheters 7 (18.4) 0
Parenteral nutrition 8 (21.1) 0
Abdominal or thoracic surgery 9 (23.7) 0
Hematopoietic transplantation 1 (2.6) 0
Intensive care unit stay 9 (23.7) 0
Neutropeniad 4 (10.5) 0
Acute renal failure 2 (5.3) 0
OUTCOME OF HOSPITAL STAY
Death 11 (28.9) n.a.
Discharge 27 (71.1) n.a.
a Includes the following diseases: pneumonia, chronic obstructive pulmonary disease, and
acute respiratory distress syndrome.
b Includes the following diseases: cholecystitis, angiocholitis, pancreatitis, and peritonitis.
c Includes the following diseases: acute renal insufficiency and diabetes mellitus.
dDefined as an absolute neutrophil count below 500 cells/mm3.
n.a., Not applicable.
Identification of Candida Species
The collected blood samples were inoculated in a BacT/Alert
3D240 automated blood culture system (BioMerieux, France) for
Candida growth detection. CHROMagar Candida medium was
used to isolate and identify of Candida species from positive
cultures. Candida species were further confirmed with a Vitek-2
system (BioMerieux, France).
Generation of Recombinant Enolase
Recombinant enolase protein was generated and purified as
described in our previous work (He et al., 2015).
Preparation of Detector and Capture
Reagents
The detector reagent, 30-nm diameter colloidal gold particles
labeled with mouse anti human IgG monoclony antibody
(8µg/ml), the gold solution pH was adjusted to 8.5. The test
capture reagent, purified rEno protein, was diluted with 20mM
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phosphate-buffered solution (PBS) (pH7.4) to 0, 0.5, 1.0, 1.5, and
2.0mg/ml and stored at −20◦C until required. Goat anti mouse
IgG antibody was used as the control capture reagent and diluted
to working concentrations of 0, 0.5, 1.0, 1.5, and 2.0mg/ml with
PBS (pH7.2). The diluted IgG solutions were stored at −80◦C
until later use.
Preparation of the Conjugate Pad and
Immobilization of the Capture Reagents
onto Nitrocellulose Membranes
The gold conjugated mouse anti human antibody solution was
dispensed onto glass fiber paper (300 × 5mm) at a speed of
10µl per cm using an XYZ3050 Dispense Workstation (BioDot
Shanghai, China), and the conjugate pad was dried under a
vacuum. Different working concentrations of both the test and
control capture reagents were dispensed onto nitrocellulose
membrane strips (300 × 25mm) at a speed of 0.80ml solution
per cm. After drying for 2 h at 37 C, the membrane strips were
blocked by incubation in 20mM PBS (pH 7.5) containing 2%
(w/v) nonfat dried milk for 25min and washed three times with
PBS containing 0.1% (v/v) Tween-20 for 3min at a time. The
membrane was dried for 2 h at 37◦C and stored at 4◦C
Preparation of the Lateral Flow
Immunoassay Strip
The LFIA consisted of a sample pad, conjugate pad, immobilized
nitrocellulose membrane, and absorbent pad. A schematic
diagram of the LFIA is shown in Figure 1A. The prepared strips
were stored dry at 4◦C until required.
Detection Principle and Test Procedure
During the test, the sample solution was pipetted onto the sample
pad. For a positive sample, the human anti Eno IgG reacted with
the (Au)-mouse anti human IgG antibody conjugate to form a
complex when the sample flows through the conjugate pad. Then,
the complex was captured by rEno, forming a red band at the test
line. Otherwise, no signal could be seen in the test line when a
negative sample was used. Excess (Au)-mouse anti human IgG
antibody conjugate binds goat anti mouse IgG in the control line,
forming another red band (Figure 1B). Therefor, for the LFIA
developed in this study, the appearance of two red bands in the
read-out zone indicates a positive test and only one red band in
the control line indicates a negative test (Figure 1C). In practical
terms, the LFIA is laid on a flat bench and 100µl of serum is
added to the sample hole. The result is available in 15min.
Enzyme-Linked Immunosorbent Assay
(ELISA)
ELISA was performed as described in our previous work to detect
the anti Eno IgG level in the sera of subjects enrolled in this
research study (He et al., 2015). Briefly, rEno was adjusted to
the concentration of 500 ng/mL in the bicarbonate buffer (pH9.6)
and used to coat ELISA plates. After blocking with 3% BSA/PBS-
T, 1:400 pre-diluted human sera was added to the plates and
1:10,000 diluted peroxidise conjugate goat anti human antibody
was used as the secondary antibody. After the reaction was
terminated with 2 N H2SO4, the microplates were read at a
wavelength of 450 nm using an ELISA reader (VersaMax plate
reader, Molecular Devices Co.).
Specificity and Sensitivity of Lateral Flow
Immunoassay Strip and Its Agreement with
Reference Methods
The strips were used to detect antibody in 38 IC patient serum
samples and 50 control serum samples. Samples were tested
by LFIA and ELISA in triplicate. The specificity, sensitivity,
positive predictive value (PPV) and negative predictive value
(NPV) of LFIA were calculated and compared with those of
ELISA or blood culture results. The correlations between LFIA
and ELISA or LFIA and blood culture were determined using κ
statistical analysis (Viera and Garrett, 2005). Statistical analysis
was performed using GraphPad Prism 5.0.
RESULTS
Optimal Concentrations of Capture
Reagents for Immobilization
Preliminary experiments established that 1.0mg/mL goat anti
mouse IgG was the optimal concentration for immobilization
as the control capture reagent (data not shown). To optimize
the concentration of the test capture reagent, rEno, at different
concentrations of 0, 0.5, 1.0, 1.5, and 2.0mg/ml was immobilized
and used to test the sera from proven IC patients and control
subjects. The corresponding test sensitivity, specificity and
Youden index were calculated and are summarized in Table 2.
The Youden test indicates the discriminatory accuracy of a
diagnostic assay and offers an optimal cut-point value: we defined
the optimal concentration of rEno as 1.0mg/ml in this study.
LFIA Test for Blood Culture Positive and
Negative Samples
A positive LFIA test result was found in 27 of 38 serum samples
from proven IC patients, including 11 C. albicans, 5 C. tropicalis,
5 C. parapsilosis, 3 C. glabrata, 2 C. lusitaniae, and 1 C. Krusei
infected sample(s). For the 50 control subjects without Candida
infection, the LFIA test results were all negative, except two
serum samples were determined as weakly positive. As a result,
the sensitivity, specificity, PPV, and NPV of the LFIA diagnostic
test based on detecting antibody against Candida enolase were
71.1, 96.0, 93.1, and 81.4%, respectively.
Detection of Eno Antibody by ELISA
Figure 2A indicates the results obtained with the serum samples
drawn from 38 IC patients and 50 control subjects who were
tested by ELISA for detecting Eno IgG antibodies. The median
of the antibody absorbance for sera from IC patients (median
0.734; interquartile range, 0.521–0.843) was significantly higher
than that from control individuals (median 0.295; interquartile
range, 0.203–0.388; P < 0.001).
To evaluate the predictive ability of the enolase antibody to
the risk IC, we assessed the area under the curve (AUC) using
the receiver operating characteristic curve (ROC) (Mandrekar,
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FIGURE 1 | Design of the lateral flow immunoassay strip. (A) Schematic diagram. The conjugate pad was dispensed with gold conjugated mouse anti human
antibody solution. At the test line and control line position, rEno and goat anti mouse IgG were immobilized, respectively. (B) The test principle of the lateral flow
immunoassay strip. Human anti Eno IgG present in the sample react and bind to the gold conjugated mouse anti human IgG, then, it was captured by immobilized
rEno, forming a positive result in the test line. Immobilized goat anti mouse IgG captures gold-conjugated mouse anti human IgG, forming the control line.
(C) Interpretation of the results. i, positive (2 red bands at the readout zone) and ii, negative (only the control line area shows a red band).
TABLE 2 | Performances on sera using different test capture reagent
(rEno) concentration.
Concentration Sensitivity (%) Specificity (%) Youden index*
0 0 100 0
0.5 29.0 100 0.29
1.0 71.1 95.0 0.66
1.5 76.3 84.0 0.60
2.0 84.2 74.0 0.58
*Youden index was defined as J (t) = sensitivity + specificity −1.
2010). The sensitivity and specificity were calculated based on
the ROC curve. The ROC curve for the enolase antibody in IC
diagnosis is shown in Figure 2B and the AUC is 0.907 with a 95%
confidence interval of 0.840–0.974. Considering a cutoff value
of 0.476, the sensitivity, specificity, PPV and NPV of the ELISA
diagnostic test were 86.8, 90.0, 86.8, and 90.0%, respectively.
Agreement between the Lateral Flow
Immunoassay and Reference Methods
For the 88 clinical sera from IC patients and control subjects,
29 were antibody positive and 59 were negative according to
LFIA, whereas 33 were positive and 55 were negative according
to ELISA. Additionally, 28 were positive and 54 were negative
in both tests. Therefore, the specificity and sensitivity of LFIA,
compared with ELISA, were 98.2 and 84.8%, respectively. There
was an excellent correlation (κ = 0.851) between the LFIA and
ELISA.
The blood culture demonstrated 38 subjects were positive
and 50 were negative (88 subjects in total), 27 subjects were
determined positive and 48 were negative by both LFIA and
blood culture tests. In addition, LFIA gave positive results for
two blood culture negative samples and 11 negative results for
blood culture positive subjects. A strong agreement (κ = 0.690)
was observed between the blood culture and LFIA test results
(Table 3).
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FIGURE 2 | ELISA test results for the study subjects. (A) Antibody levels in the study subjects. The anti Eno levels for the sera from IC patients were significantly
higher than those in control individuals (P < 0.001). (B) The receiver operating curve (ROC) was used to identify the anti Eno positive and negative subjects. The area
under the curve (AUC) was 0.907 with a cutoff value of 0.476.
TABLE 3 | Results of Eno antibody detection and clinical blood sample culture.
ELISA* Blood culture
Positive Negative Total Positive Negative Total
LFIA* Positive 28 1 29 LFIA Positive 27 2 29
Negative 5 54 59 Negative 11 48 59
Total 33 55 88 Total 38 50 88
*ELISA, enzyme-linked immunosorbent assay; LFIA, lateral flow immunoassay.
LFIA compared to ELISA, κ = 0.851; LFIA compared to blood culture, κ = 0.690.
DISCUSSION
IC is a serious cause of morbidity and mortality. Unfortunately,
the laboratory technology for diagnosing IC cannot meet the
current need for clinical applications (Clancy and Nguyen, 2013).
To address the problem, the development of simple, rapid,
sensitive and accurate diagnostic methods for IC has become an
urgent focus.
As a rapid and simple detectionmethod, LFIA has increasingly
been used for detecting various human-associated infective
pathogens (Ngom et al., 2010; Huang et al., 2016). In the present
study, we developed a LFIA for diagnosing IC, which uses
rEno protein to detect the corresponding antibody in the serum
specimens of the IC patients. The rEno and a control antibody
(goat anti mouse IgG) were immobilized on a membrane support
as two distinct lines and were then combined with a sample
pad, a conjugate pad that was impregnated with visualizing
goad particles conjugated to monoclonal antibody of mouse anti
human IgG and an absorbent pad to create the test strip.
Several studies have indicated that C. albicans enolase, a cell
wall associated protein, is a promising candidate molecule for
diagnosing IC, even in patients with neutropenia and immune
defects (Laín et al., 2007; Clancy et al., 2008; Li et al., 2013).
According to our previous work (He et al., 2015), enolase proved
to be an immuno-dominant protein compared to other cell wall
associated proteins, which makes enolase more applicable to
serodiagnosis research. Using the rEno as the test capture reagent,
we detect the antibody against enolase in the sera of proven
IC patients and control subjects. When ELISA was used as a
reference method, the LFIA test had good specificity (98.2%) and
sensitivity (84.8%). There was excellent agreement between the
results obtained by ELISA and the LFIA (κ= 0.851). In addition,
the agreement between the results of the blood culture and the
LFIA test (κ= 0.690) is also strong. These data suggest that there
is an intense correlation between the enolase antibody levels and
Candida species infection status, suggesting that LFIA would be
valuable in IC surveillance.
For the ELISA test, the sensitivity, specificity, PPV and NPV
were 86.8, 90.0, 86.8, and 90.0%, respectively. This result was
similar to those seen in previous studies (Clancy et al., 2008; He
et al., 2015). For the LFIA test, the corresponding values were
71.1, 96.0, 93.1, and 81.4%. The higher PPV (96 vs. 90%) by the
LFIA is derived from the relatively higher false negative and lower
false positive rates than ELISA. Maximizing the PPV is essential
for reliably identifying patients who are likely to develop the
disease, which should be considered when developing screening
diagnostic methods. The LFIA test appears to be useful as a first-
step assay for patients suspected of having IC, or as part of a
diagnostic set in high-risk hosts. Clancy et al. (2008). reported
patients infected with non-C. albicans species can be identified
by responses against recombinant C. albicans antigens. In the
present study, we detected IgG antibodies against recombinant
C. albicans Eno in the sera from patients infected with non-
C. albicans species. Because the sample size in our study is not
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sufficiently large to support effective statistical analysis, whether
there is any relationship between false negative results given by
LFIA andCandida species could be the subject of further research
work.
Enolase is a highly conserved protein among different
organisms (Van der Straeten et al., 1991; Sundstrom and Aliaga,
1992). When an immune response involving enolase was applied
to the diagnosis, cross reactivity should be a source of concern.
Laín et al. (2008) think that recombinant proteins could eliminate
cross reactivity via posttranslational modifications. In a study
conducted by Li et al. (2013), it is reported that sera from
patients with bacteremia had no significant cross reactivity due
to the lower antibody titers when diagnosing IC with rEno from
C. albicans. Therefore, it can be expected to contribute low
cross reactivity in the present study with patients with bacterial
infections. It should be noted, however, that a shortcoming of the
present study is that a large investigation with a sizeable sample
size still should be conducted to confirm the aforementioned
speculation.
Various methods have been developed for diagnosing IC, such
as the ELISA protocol for antibody detection (Laín et al., 2007),
β-D-Glucan detection (Ostrosky-Zeichner et al., 2005) and PCR
(McMullan et al., 2008; Lucignano et al., 2011). However, these
methods have common disadvantages of being time-consuming,
and their uses are restricted to well-equipped laboratories. The
LFIA reagent kit is rapid and easy to use. In this regard, the LFIA
that we established is intended for use in the sero-surveillance
of IC, especially in screening large numbers of blood samples in
the field or poorly equipped laboratories. This would facilitate
effective control of IC.
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